Adult T Cell Lymphoma

Adult T cell lymphoma refers to a very rare lymphoid cancer subtype known more specifically as adult T cell leukemia/lymphoma, or ATLL. It is considered a peripheral T cell lymphoma (PTCL).

Adult T cell Leukemia/Lymphoma: What is it?

ATLL (sometimes written as ATL) has four known subtypes: acute, lymphoma, chronic, and smoldering. Prognosis for patients with the chronic or smoldering subtypes is considered to be rather good, but for the acute and lymphoma subtypes, adult T cell lymphoma is a highly aggressive cancer with an extremely poor prognosis—the average time from diagnosis to death is generally under one year. The disease is extraordinarily rare in the US; rather, it is more commonly reported in Japan and other parts of Asia.

The reason the adult T cell lymphoma is called a leukemia/lymphoma is because it is characterized by the build-up of leukemic T cells in the body but it also presents with generalized lymphadenopathy

Adult T cell Leukemia/Lymphoma: Treatments

There are not too many studies that support specific treatment options for those with adult T cell lymphoma. What has been determined is that an autologous stem cell transplantation, preceded by high-dose chemotherapy, is not effective, but that an allogenic transplant may indeed offer about 40% of patients some hope. Otherwise, Zidovudine/IFN-alpha therapy has shown some efficacy in poor prognosis patients, but the treatment for Adult T cell lymphoma has yet to be proven on a large scale.

The cause of Adult T cell Leukemia/Lymphoma

ATLL is one of the few cancers the cause of which has been almost undeniably linked to a virus, namely the Human T cell Lymphotrophic Virus-1 (HTLV-1). HTLV-1 is the first retrovirus ever to be discovered, and its discovery would be followed closely by the discovery of a few more, including the much-better-known retrovirus, human immunodeficiency virus, or HIV, in 1983.

HTLV-1 is believed to have infected as many as 15-20 million people worldwide, although estimates suggest that only about 500,000 of them will develop human T cell leukemia/lymphoma. That said, many others who are infected with the virus will develop other clinically problematic disorders, ranging from myelopathy to dermatitis to other inflammatory diseases, according to Ewa Maria Szczypinksa, MD, writing for Medscape.

Actual infection by the HTLV-1 virus generally does not get reported because the virus remains latent and doesn't cause any of its own specific adult T cell lymphoma symptoms.

Sources

Murphy EL, Hanchard B, Figueroa JP, et al. Modeling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int/ Cancer. 1989;43:250-253.

Ewa Maria Szczypinksa, MD: Human T-Cell Lymphotrophic Viruses

Tanosaki R, Tobinai K. Adult T-cell Leukemia–Lymphoma: Current Treatment Strategies and Novel Immunological Approaches. Expert Rev Hematol. 2010;3(6):743-753

Related Articles

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap